Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Vonaprument · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Vonaprument | EXPERIMENTAL | Participants will receive vonaprument IVT injections every month during the 24-month treatment period. |
| Sham Group | SHAM_COMPARATOR | Participants will receive Sham IVT injections every month during the 24-month treatment period. |
| Name | Type | Description |
|---|---|---|
| Vonaprument | DRUG | Form: solution for injection; Route of Administration: IVT injection |
| Sham Administration | OTHER | Form and Route of Administration: to mimic IVT injection (includes placement of the blunt opening of an empty, needleless syringe barrel on the conjunctiva in the inferotemporal quadrant of the eyeball to stimulate the pressure of an injection). |
Inclusion Criteria: * Diagnosis of dry AMD with GA as determined by the Investigator and confirmed by the independent Central Reading Center. Exclusion Criteria: * Geographic atrophy due to other causes than AMD such as Stargardt disease, cone-rod dystrophy, pathologic myopia, or toxic maculopath...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Regeneron Pharmaceuticals, Inc. | REGN | 2 | PHASE3 | Pozelimab, Cemdisiran |
| Annexon, Inc. | ANNX | 1 | PHASE3 | Vonaprument |
| Belite Bio, Inc. ADR | BLTE | 1 | PHASE3 | Tinlarebant |
| Johnson & Johnson | JNJ | 1 | PHASE2 | JNJ-81201887 |
| AbbVie, Inc. | ABBV | 1 | PHASE1 | ABBV-6628, SYFOVRE |
| Sanofi SA Sponsored ADR | SNY | 1 | PHASE1 | SAR446597, Sham Comparator |
| Ocugen Inc | OCGN | 1 | PHASE1 | OCU410 |
| Apellis Pharmaceuticals, Inc. | APLS | 1 | - | Pegcetacoplan |
Vonaprument is an investigational small molecule being developed for the treatment of Geographic Atrophy, a form of dry age-related macular degeneration. It is administered as an intravitreal injection. The drug is currently in Phase 3 clinical development and has not yet been approved by regulatory authorities.
Vonaprument is a small molecule designed to address Geographic Atrophy, a condition associated with dry age-related macular degeneration. The specific molecular target of Vonaprument has not been disclosed in the available information. The drug is administered via intravitreal injection to the eye.
Vonaprument is being developed by Annexon, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol ANNX. The company is conducting clinical trials to evaluate the drug's efficacy and safety in patients with Geographic Atrophy.
Vonaprument is currently in Phase 3 clinical development. It is being investigated as a treatment for Geographic Atrophy, a form of dry age-related macular degeneration. The drug has received Fast Track designation from the FDA, but it remains investigational and is not yet approved for commercial use.
Vonaprument is being studied in a Phase 3 clinical trial registered as NCT06510816. This randomized, double-blind, sham-controlled study is investigating the efficacy and safety of intravitreal injections of Vonaprument in participants with Geographic Atrophy. The trial is active but not recruiting, with an enrollment of 659 participants across multiple countries.
Yes, Vonaprument was formerly known as ANX007. The Phase 3 clinical trial NCT06510816 explicitly states that Vonaprument was previously referred to as ANX007. The drug is being developed by Annexon, Inc. for the treatment of Geographic Atrophy.